Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer

References

• JemalABrayFCenterMMWardEFormanDGlobal cancer statisticsCA Cancer J Clin201161699021296855
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med20043502129213915118073
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med200936194795719692680
   PubMed Web of Science ®Google Scholar
• LeeJSParkKKimS-WA randomized phase III study of gefitinib (IRESSA) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lungJ Thor Oncol.20094Suppl 19 Abstract PRS 4
   Google Scholar
• MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol20101112112820022809
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med20103622380238820573926
   PubMed Web of Science ®Google Scholar
• ZhouCCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol20111273574221783417
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutations-positive non-small cell lung cancer (EURTAC) a multicenter, open-label, randomized phase 3 trialLancet Oncol20121323924622285168
   PubMed Web of Science ®Google Scholar
• YangJC-HSchulerMHYamamotoNLUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutationsJ Clin Oncol201230Suppl Abstract LBA7500
   Google Scholar
• KwakELSordellaRBellDWIrreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinibProc Natl Acad Sci U S A20051027665767015897464
   PubMed Web of Science ®Google Scholar
• KobayashiSBoggonTJDayaramTEGFR mutation and resistance of non-small-cell lung cancer to gefitinibN Engl J Med200535278679215728811
   PubMed Web of Science ®Google Scholar
• BalakMNGongYRielyGJNovel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinoma with acquired resistance to kinase inhibitorsClin Cancer Res2006126494650117085664
   PubMed Web of Science ®Google Scholar
• EngelmanJAZajnullahuKMitsudomiTMET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingScience20073161039104317463250
   PubMed Web of Science ®Google Scholar
• SequistLVWaltmanBADias-SantagataDGenotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsSci Transl Med2011375ra26
   PubMed Web of Science ®Google Scholar
• WangWLiQYamadaTCrosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitorsClin Cancer Res2009156630663819843665
   PubMed Web of Science ®Google Scholar
• XuLKikuchiEXuCCombined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and METCancer Res2012723302331122552292
   PubMed Web of Science ®Google Scholar
• JanjigianYYSmitEFHornLActivity of afatinib/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitorsAnn Oncol201223Suppl 9ix401 Abstract 12270
   Google Scholar
• SpigelDRErvinTJRamlauRFinal efficacy results from OAM4558 g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLCJ Clin Oncol201129Suppl Abstract 7505
   Google Scholar
• KwakELCamidgeDRClarkJClinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066J Clin Oncol200927Suppl Abstract 3509
   Google Scholar
• EderJPVande WoudeGFBoernerSALoRussoPMNovel therapeutic inhibitors of the c-Met signaling pathway in cancerClin Cancer Res2009152207221419318488
   PubMed Web of Science ®Google Scholar
• YakesFMChenJTanJCabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growthMol Cancer Ther2011102298230821926191
   PubMed Web of Science ®Google Scholar
• KollmannsbergerCKHurwitzHVlahovicGPhase I study of daily administration of MGCD265 to patients with advanced malignancies (Study 265-101)J Clin Oncol200927Suppl Abstract e14525
   Google Scholar
• SequistLVvon PawelJGarmeyEGRandomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non–small-cell lung cancerJ Clin Oncol2011293307331521768463
   PubMed Web of Science ®Google Scholar
• DateKMatsumotoKShimuraHTanakaMNakamuraTHGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factorFEBS Lett1997420169450538
   PubMed Web of Science ®Google Scholar
• TanEParkKLimWTPhase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLCJ Clin Oncol201129Suppl 15 Abstract 7571
   Web of Science ®Google Scholar
• MaPCMaulikGChristensenJSalgiaRc-Met: structure, functions and potential for therapeutic inhibitionCancer Metastasis Rev200322209325
   Web of Science ®Google Scholar
• SattlerMMaPCSalgiaRTherapeutic targeting of the receptor tyrosine kinase MetCancer Treat Res200411912113815164876
   PubMedGoogle Scholar
• NakamuraTNawaKIchiharaAKaiseNNishinoTPurification and subunit structure of hepatocyte growth factor from rat plateletsFEBS Lett19872243113163319692
   PubMed Web of Science ®Google Scholar
• GohdaETsubouchiHNakayamaHHuman hepatocyte growth factor in plasma from patients with fulminant hepatic failureExp Cell Res19861661391503527727
   PubMed Web of Science ®Google Scholar
• StokerMGherardiEPerrymanMGrayJScatter factor is a fibroblast-derived modulator of epithelial cell mobilityNature19873272392422952888
   PubMed Web of Science ®Google Scholar
• JiangWHiscoxSMatsumotoKNakamuraTHepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancerCrit Rev Oncol–Hematol19992920924810226727
   PubMed Web of Science ®Google Scholar
• MatsumotoKDateKOhmichiHNakamuraTHepatocyte growth factor in lung morphogenesis and tumor invasion: role as a mediator in epithelium-mesenchyme and tumor-stroma interactionsCancer Chemother Pharmacol199638SupplS42S478765416
   PubMed Web of Science ®Google Scholar
• ComoglioPMBoccaccioCScatter factors and invasive growthSeminar Cancer Biol201111153165
   Web of Science ®Google Scholar
• ZhangYWVande WoudeGFHGF/SF-met signaling in the control of branching morphogenesis and invasionJ Cell Biochem20038840841712520544
   PubMed Web of Science ®Google Scholar
• NakashiroKHaraSShinoharaYPhenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22RAm J Pathol200416553354015277227
   PubMed Web of Science ®Google Scholar
• NaldiniLVignaENarsimhanRPHepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-METOncogene199165015041827664
   PubMed Web of Science ®Google Scholar
• MaPCJagadeeswaranRJagadeeshSFunctional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancerCancer Res2005651479148815735036
   PubMed Web of Science ®Google Scholar
• SmolenGASordellaRMuirBAmplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752Proc Natl Acad Sci U S A20061032316232116461907
   PubMed Web of Science ®Google Scholar
• MichieliPBasilicoCPennacchiettiSMutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonistsOncogene1999185221523110498872
   PubMed Web of Science ®Google Scholar
• BoccaccioCGaudinoGGambarottaGGalimiFComoglioPMHepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGFJ Biol Chem199426912846128518175699
   PubMed Web of Science ®Google Scholar
• TuckABParkMSternsEEBoagAElliottBECoexpression of hepatocyte growth factor and receptor (Met) in human breast carcinomaAm J Pathol19961482252328546209
   PubMed Web of Science ®Google Scholar
• KoochekpourSJeffersMRulongSMet and hepatocyte growth factor/scatter factor expression in human gliomasCancer Res199757539153989393765
   PubMed Web of Science ®Google Scholar
• NavabRLiuJSeiden-LongICo-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cellsNeoplasia2009111292130020019837
   PubMed Web of Science ®Google Scholar
• OkudaKSasakiHYukiueHYanoMFujiiYMet gene copy number predicts the prognosis for completely resected non-small cell lung cancerCancer Sci2008992280228519037978
   PubMed Web of Science ®Google Scholar
• CappuzzoFMarchettiASkokanMIncreased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patientsJ Clin Oncol2009271667167419255323
   PubMed Web of Science ®Google Scholar
• ToiMTaniguchiTUenoTSignificance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancerClin Cancer Res199846596649533534
   PubMed Web of Science ®Google Scholar
• YamashitaJOgawaMYamashitaSImmunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancerCancer Res199454163016338137271
   PubMed Web of Science ®Google Scholar
• TaniguchiTKitamuraMAraiKIncrease in the circulating level of hepatocyte growth factor in gastric cancer patientsBr J Cancer1997756736779043023
   PubMed Web of Science ®Google Scholar
• GohjiKNomiMNiitaniYIndependent prognostic value of serum hepatocyte growth factor in bladder cancerJ Clin Oncol2000182963297110944129
   PubMed Web of Science ®Google Scholar
• ToiyamaYMikiCInoueYOkugawaYTanakaKKusunokiMSerum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patientsInt J Cancer20091251657166219569242
   PubMed Web of Science ®Google Scholar
• BhartiAMaPCMaulikGHaptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancerAnticancer Res2004241031103815154618
   PubMed Web of Science ®Google Scholar
• SeidelCBørsetMTuressonIAbildgaardNSundanAWaageAElevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study GroupBlood1998918068129446640
   PubMed Web of Science ®Google Scholar
• SiegfriedJMWeissfeldLASingh-KawPWeyantRJTestaJRLandreneauRJAssociation of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancerCancer Res1997574334399012470
   PubMed Web of Science ®Google Scholar
• OnitsukaTUramotoHOnoKComprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET and hepatocyte growth factor statusJ Thorac Oncol2010559159620150826
   PubMed Web of Science ®Google Scholar
• HosodaHIzumiHTukadaYPlasma hepatocyte growth factor elevation may be associated with early metastatic disease in primary lung cancer patientsAnn Thorac Cardiovasc Surg2012181721959198
   PubMed Web of Science ®Google Scholar
• UjiieHTomidaMAkiyamaHSerum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancerAnticancer Res2012323251325822843899
   PubMed Web of Science ®Google Scholar
• MinutiGCappuzzoFDuchnowskaRIncreased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancerBr J Cancer201210779379922850551
   PubMed Web of Science ®Google Scholar
• TurkeABZejnullahuKWuYLPreexistence and clonal selection of MET amplification in EGFR mutant NSCLCCancer Cell201017778820129249
   PubMed Web of Science ®Google Scholar
• YanoSWangWLiQIHepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutationsCancer Res2008689479948719010923
   PubMed Web of Science ®Google Scholar
• YanoSYamadaTTakeuchiSHepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohortJ Thorac Oncol201162011201722052230
   PubMed Web of Science ®Google Scholar
• MasagoKTogashiYFujitaSClinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinibMed Oncol2012291614162121779929
   PubMed Web of Science ®Google Scholar
• KasaharaKAraoTSakaiKImpact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non–small cell lung adenocarcinomaClin Cancer Res2010164616462420679350
   PubMed Web of Science ®Google Scholar
• HanJYKimJYLeeSHYooNJChoiBGAssociation between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancerLung Cancer20117429329921440951
   PubMed Web of Science ®Google Scholar
• WittaSEGemmillRMHirschFRRestoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell linesCancer Res20066694495016424029
   PubMed Web of Science ®Google Scholar
• ThomsonSBuckEPettiFEpithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibitionCancer Res2005659455946216230409
   PubMed Web of Science ®Google Scholar
• FujitaYSudaKKimuraHHighly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutationJ Thorac Oncol201271640164422899358
   PubMed Web of Science ®Google Scholar
• CappuzzoFJannePASkokanMMET increased gene copy number and primary resistance to gefitinib therapy in non-small cell lung cancer patientsAnn Oncol20092029830418836087
   PubMed Web of Science ®Google Scholar
• OkamotoWOkamotoITanakaKTAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutationMol Cancer Ther201092785279220716641
   PubMed Web of Science ®Google Scholar
• StabileLPRothsteinMEKeohavongPTargeting of both the c-Met and EGFR pathways results in additive inhibition of lung tumorigenesis in transgenic miceCancers (Basel)201022153217021390244
   PubMedGoogle Scholar
• ElezETaberneroJPrudkinLPharmacodynamic (PD) – pharmacokinetic (PK) study of ficlatuzumab (F), a monoclonal antibody (MAB) directed to the hepatocyte growth factor (HGF), in patients (Pts) with advanced solid tumors who have live metastases (Mets)Ann Oncol201223Suppl 9ix154 Abstract 443PD
   Google Scholar
• MeetzeKABoudrowAConnolyKAnti-tumor activity of SCH 900105 (AV299), an anti-HGF antibody, in non-small cell lung cancer modelsMol Cancer Ther.20098Suppl 12 Abstract C173
   Web of Science ®Google Scholar
• PatnaikAWeissGJPapadopoulosKPhase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumorsJ Clin Oncol.201028Suppl Abstract 2525
   Google Scholar
• MokTSKParkKGeaterSLA randomized phase (Ph) 2 study with exploratory biomarker analysis of ficlatuzumab (F) a humanized hepatocyte growth factor (HGF) inhibitory MAB in combination with gefitinib (G) versus G in Asian patients (pts) with lung adenocarcinoma (LA)Ann Oncol.201223Suppl 9ix391 Abstract 1198P
   Google Scholar
• EngelmanJAJannePAMechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerClin Cancer Res2008142895289918483355
   PubMed Web of Science ®Google Scholar
• CappuzzoFJännePASkokanMMET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patientsAnn Oncol20092029830418836087
   PubMed Web of Science ®Google Scholar